Howard Fillit MD
Founding Executive Director and Chief Science Officer Alzheimer's Drug Discovery Foundation
Join to View Full Profile
Alzheimer's Drug Discovery Foundation, 57 West 57 Street904New York, NY 10019
Phone+1 212-901-8000
Dr. Fillit is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Nephrology, 1979 - 1980
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1974 - 1976
SUNY Upstate Medical UniversityClass of 1974
Certifications & Licensure
NY State Medical License 1975 - 2025
FL State Medical License 2018 - 2024
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery founda...Jeffrey Cummings, Michael Gold, Mark Mintun, Michael Irizarry, Andrew von Eschenbach
The Journal of Prevention of Alzheimer's Disease. 2025-01-01 - 5 citationsRelationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients.Dawn C Matthews, Jefferson W Kinney, Aaron Ritter, Randolph D Andrews, Erin N Toledano Strom
Alzheimer's & Dementia. 2024-07-09 - 1 citationsRacial and ethnic differences in disease course Medicare expenditures for beneficiaries with dementia.Natalia Olchanski, Yingying Zhu, Lichen Liang, Joshua T Cohen, Jessica D Faul
Journal of the American Geriatrics Society. 2024-04-01
Authored Content
- We Finally Have New Alzheimer’s Drugs. How Do We Decide Who Gets Them?July 2023
- It’s Time to Move Past Aduhelm and Focus on a Broader Alzheimer’s Drug PipelineJune 2022
- We Need New Biomarkers for Alzheimer's DiseaseSeptember 2018
- In the Search for Alzheimer’s Drugs, Researchers Must Look Beyond Beta AmyloidNovember 2017
- Join now to see all
Press Mentions
Alzheimer’s-related Dementia Could Be Prevented by Experimental Drug, Researchers SayMarch 22nd, 2025
The ADDF's Diagnostics Accelerator Authors New Paper on Ocular Biomarker Landscape, Highlighting Ocular Tests as a Tool for Early Detection of Alzheimer's DiseaseMarch 12th, 2025- Inaugural ADDF Scientific Summit Convenes Pioneering Scientists Leading and Shaping Alzheimer's ResearchMarch 6th, 2025
- Join now to see all
Grant Support
- Drug Discovery For NeurodegenerationNational Institute On Aging2007–2011
- Drug Discovery For NeurodegenerationNational Institute On Aging2010
- Immunobiology Of Autoimmunity To Heparan SulfateNational Institute Of Allergy And Infectious Diseases1994–1997
- Autoimmunity To Proteoglycans In Autoimmune DiseaseNational Institute Of Allergy And Infectious Diseases1991–1993
- Pilot Study -- Heparan Sulfate Proteoglycans In Alzheimer'S DiseaseNational Institute On Aging1989–1993
- Specificity Of Human Autoantibodies To ProteoglycansNational Institute Of Allergy And Infectious Diseases1990–1992
- Neuroendocrine And Neuroimmune Studies Of Alzheimers Disease And AgingNational Center For Research Resources1987–1988
- Immunological Probes In Alzheimer'S DiseaseNational Center For Research Resources1985–1988
- Immunological Studies In GlomerulonephritisNational Center For Research Resources1985–1986
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
